Mark Feinberg

Title: Mark Feinberg: Innovator in SARS-CoV-2 Vaccine Development

Introduction

Mark Feinberg is a notable inventor based in New York, NY (US). He has made significant contributions to the field of vaccine development, particularly in relation to SARS-CoV-2. His innovative work has the potential to impact public health positively.

Latest Patents

Mark Feinberg holds a patent for "Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins." This patent provides a framework for developing vaccines against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The invention includes recombinant vesicular stomatitis virus (VSV) vectors that encode the SARS-CoV-2 spike (S) protein or its immunogenic variants. These vaccines aim to induce an immune response, prevent infection, and facilitate the production of adaptive mutants of the recombinant VSV particles.

Career Highlights

Throughout his career, Mark Feinberg has worked with prominent organizations such as the International Aids Vaccine Initiative and Merck Sharp & Dohme Corporation. His experience in these institutions has allowed him to collaborate with leading experts in the field of vaccine research and development.

Collaborations

Mark has collaborated with notable coworkers, including Christopher Lee Parks and Maoli Yuan. Their combined expertise has contributed to advancements in vaccine technology and research.

Conclusion

Mark Feinberg's innovative work in vaccine development, particularly concerning SARS-CoV-2, showcases his commitment to improving public health. His contributions through patents and collaborations highlight the importance of innovation in combating global health challenges.